<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / antmaid0 / All</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Sat, 05 Sep 2020 02:13:21 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-2"><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></source>
	<description><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results from testing a unique lot. The dotted lines represent the quality range established based on the adalimumab (US) lots tested (mean ?3 standard deviations). Adalimumab (EU) EU-authorized adalimumab, adalimumab (US) FDA-licensed adalimumab, CDC complementdependent cytotoxicityFunctional Characterization of ABP 501, Bios ]]></description>
	<pubDate>Sat, 05 Sep 2020 02:13:21 +0000</pubDate>
	<author>antmaid0</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-2</guid>
</item>

<item>
	<title><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-6"><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></source>
	<description><![CDATA[Een shown to be similar to adalimumab with respect to binding to a panel of Fc receptors, including FccRIa, FccRIIa, FccRIIIa (158V) (with and without TNFa), and FccRIIIa (158F). Importantly, effector function activation (ADCC and CDC) was also demonstrated to be similar between ABP 501 and adalimumab using highly sensitive methods. The ADCC and CDC methods have been demonstrated to be sensitive t ]]></description>
	<pubDate>Sat, 05 Sep 2020 01:23:09 +0000</pubDate>
	<author>antmaid0</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-6</guid>
</item>

<item>
	<title><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-4</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-4"><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></source>
	<description><![CDATA[Een shown to be similar to adalimumab with respect to binding to a panel of Fc receptors, including FccRIa, FccRIIa, FccRIIIa (158V) (with and without TNFa), and FccRIIIa (158F). Importantly, effector function activation (ADCC and CDC) was also demonstrated to be similar between ABP 501 and adalimumab using highly sensitive methods. The ADCC and CDC methods have been demonstrated to be sensitive t ]]></description>
	<pubDate>Sat, 05 Sep 2020 01:22:53 +0000</pubDate>
	<author>antmaid0</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-4</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Thu, 03 Sep 2020 22:13:35 +0000</pubDate>
	<author>antmaid0</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5</guid>
</item>

</channel>
</rss>
